Y Intercept Hong Kong Ltd Takes Position in Elevance Health, Inc. $ELV

Posted by George Bondi on Jul 4th, 2026

Y Intercept Hong Kong Ltd bought a new position in Elevance Health, Inc. (NYSE:ELV – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,500 shares of the company’s stock, valued at approximately $8,343,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Kemnay Advisory Services Inc. bought a new stake in Elevance Health in the fourth quarter valued at $31,000. J.Safra Asset Management Corp acquired a new position in Elevance Health during the fourth quarter worth $32,000. ORG Partners LLC lifted its holdings in shares of Elevance Health by 120.4% during the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in shares of Elevance Health in the 4th quarter valued at $38,000. Finally, Dorato Capital Management acquired a new stake in shares of Elevance Health in the 4th quarter valued at $41,000. Institutional investors own 89.24% of the company’s stock.

Insider Activity at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the sale, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.34% of the stock is owned by company insiders.

Elevance Health Stock Performance

Elevance Health stock opened at $416.97 on Friday. The stock has a 50-day simple moving average of $391.29 and a 200 day simple moving average of $351.14. The stock has a market capitalization of $90.55 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $427.19.

Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend was Wednesday, June 10th. Elevance Health’s dividend payout ratio is 29.26%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Barclays increased their target price on shares of Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Evercore restated a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Bank of America upped their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Mizuho lifted their target price on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research note on Monday, June 8th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $419.16.

Get Our Latest Stock Report on ELV

Elevance Health Company Profile

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.